In 2025, Kiniksa Pharmaceuticals International completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
However, Kiniksa Pharmaceuticals International has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2025 | 2024 |
|---|---|---|
Total Scope 1 | 1,256a | 58a |
Total Scope 2 | ||
Market-Based | 215a | 218a |
Location-Based | N/A | N/A |
Total Scope 3 | 26,922a | 28,806a |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 1.8537a | 0.137a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Kiniksa Pharmaceuticals International amounted to 1,471 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Kiniksa Pharmaceuticals International increased by 432.97%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2025, the total Scope 1 emissions of Kiniksa Pharmaceuticals International were 1,256 metric tons of CO₂ equivalent (tCO₂e).a
Compared to the previous year (2024), Kiniksa Pharmaceuticals International's Scope 1 emissions increased by 2,065.52%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2025, Kiniksa Pharmaceuticals International reported Scope 2 greenhouse gas (GHG) emissions of 215 tCO₂e using the market-based method.a
Compared to the previous year (2024), Kiniksa Pharmaceuticals International's Scope 2 emissions (Market-Based) have remained relatively stable, indicating that Kiniksa Pharmaceuticals International's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2025, Kiniksa Pharmaceuticals International reported its Scope 2 emissions using the market-based method.a
In 2025, Kiniksa Pharmaceuticals International reported 26,922 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2025 disclosure of Kiniksa Pharmaceuticals International includes a breakdown across 0 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2024, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2025, Kiniksa Pharmaceuticals International reported total Scope 3 emissions of 26,922 metric tons of CO₂ equivalent (tCO₂e).a
Compared to the previous year (2024), Kiniksa Pharmaceuticals International's Scope 3 emissions remained relatively stable, indicating that Kiniksa Pharmaceuticals International's emissions have plateaued with no significant change in its value chain footprint.a
In 2025, Kiniksa Pharmaceuticals International reported Scope 1 greenhouse gas (GHG) emissions of 1,256 tCO₂e and total revenues of USD 678 millions. This translates into an emissions intensity of 1.85 tCO₂e per millions USD.a
In 2025, Kiniksa Pharmaceuticals International reported a Scope 1 emissions intensity of 1.85 tCO₂e per millions USD. Compared to the peer group median of 12.3, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2025, Kiniksa Pharmaceuticals International ranked 5 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Kiniksa Pharmaceuticals International among the top performers, with one of the lowest emissions intensities relative to peers.a
In 2025, Kiniksa Pharmaceuticals International reported a total carbon footprint of 28,393 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 2.37% decrease compared to 2024, indicating progress in reducing its overall greenhouse gas output.a
The largest contributor to Kiniksa Pharmaceuticals International's total carbon footprint was Scope 3 emissions, accounting for 94.82% of the company's total carbon footprint, followed by Scope 1 emissions at 4.42%.a